Zomig (zolmitriptan) is an oral, selective 5-hydroxytryptamine _1B/1D (5-HT _1B/1D ) receptor agonist or 'triptan' for acute treatment of migraine attacks with or without aura. Zomig is now available in over 80 countries and is the leading second-generation triptan.

Zomig tablets were first launched in 1997 and are now widely available worldwide. Other trade marks include Zomigon (Greece and Argentina) and AscoTop (Germany).

Zomig Rapimelt is a convenient tablet formulation that dissolves quickly on the tongue and has a pleasant orange flavour, enabling it to be taken without the need for liquid. Zomig Rapimelt is widely available, being launched in more than 20 countries including Japan.

In addition, the Zomig Nasal Spray formulation, which offers fast acting, patient-friendly migraine relief, was first launched in Sweden in January 2002, and is now available in the UK, US, Germany and Austria with other major markets expected to follow.